Overview

Open-Label Long-Term Safety Study of AXS-07 for the Acute Treatment of Migraine

Status:
Completed
Trial end date:
2020-09-22
Target enrollment:
Participant gender:
Summary
Study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following repeated treatment of migraine attacks.
Phase:
Phase 3
Details
Lead Sponsor:
Axsome Therapeutics, Inc.
Treatments:
Meloxicam
Rizatriptan